What's new

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 16, Status: Authorised

May 28, 2025 - 17:35
 0
Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 16, Status: Authorised
Read More

Tags:

Previous Article

FDA leaders seek industry input on ‘listening tour’

Next Article

Human medicines European public assessment report (EPAR): Efficib, sitagliptin,m...

Related Posts

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

May 19, 2025  0

PSUSA/00010571/202407

PSUSA/00010571/202407

May 12, 2025  0

Quality of medicines questions and answers: Part 2

Quality of medicines questions and answers: Part 2

May 28, 2025  0